Editas Medicine

$66.32
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.

+$1.97 (+3.09%) Today

+$0.56 (+0.85%) As of 9:41 AM UTC after-hours

Why Robinhood?

You can buy or sell EDIT and other stocks, options, and ETFs commission-free!

About EDIT

Editas Medicine, Inc. engages in the development and commercialization of genome editing technology. Its technology includes clustered, regularly interspaced short palindromic repeats (CRISPR), and CRISPR associated protein 9 (Cas9). The company was founded by Feng Zhang, Jennifer A. Doudna, George McDonald Church, J. Keith Joung and David R. Liu in September 2013 and is headquartered in Cambridge, MA. The listed name for EDIT is Editas Medicine, Inc. Common Stock.

CEO

Cynthia L. Collins

Employees

208

Headquarters

Cambridge, Massachusetts

Founded

2013

Market Cap

4.64B

Price-Earnings Ratio

—

Dividend Yield

—

Average Volume

4.16M

High Today

$66.64

Low Today

$63.44

Open Price

$64.35

Volume

3.28M

52 Week High

$99.95

52 Week Low

$14.01

Collections

Analyst Ratings

58%

of 12 ratings

Buy

58%

Hold

33%

Sell

EDIT Earnings

-$0.79

-$0.49

-$0.18

$0.12

Q2 FY19

Q3 FY19

Q4 FY19

Q1 FY20

Q2 FY20

Q3 FY20

Q4 FY20

Estimated

— per share

Actual

Expected Feb 25, After Hours